Evoke Pharma Inc. Files 8-K on Major Corporate Events
| Field | Detail |
|---|---|
| Company | Evoke Pharma Inc |
| Form Type | 8-K |
| Filed Date | Dec 17, 2025 |
| Risk Level | high |
| Pages | 7 |
| Reading Time | 9 min |
| Key Dollar Amounts | $0.0001, $11.00 |
| Sentiment | mixed |
Sentiment: mixed
Topics: acquisition, delisting, change-of-control, corporate-governance
TL;DR
Evoke Pharma's 8-K signals major changes: asset deals, listing rule issues, control shifts, and exec changes.
AI Summary
Evoke Pharma Inc. filed an 8-K on December 17, 2025, reporting several material events. These include the completion of an acquisition or disposition of assets, a notice of delisting or failure to meet listing standards, material modifications to security holder rights, and changes in control of the registrant. The filing also covers departures of directors or officers, election of directors, appointment of officers, compensatory arrangements, and amendments to articles of incorporation or bylaws.
Why It Matters
This 8-K filing indicates significant corporate restructuring or strategic shifts at Evoke Pharma, potentially impacting its stock, operations, and investor relations.
Risk Assessment
Risk Level: high — The filing details multiple significant events including potential delisting, changes in control, and asset dispositions, all of which carry substantial risk.
Key Players & Entities
- Evoke Pharma Inc. (company) — Registrant
- December 17, 2025 (date) — Date of earliest event reported
FAQ
What specific assets were acquired or disposed of by Evoke Pharma?
The filing does not specify the details of the assets acquired or disposed of, only that such an event has occurred.
What are the reasons for Evoke Pharma's potential delisting or failure to meet listing standards?
The filing indicates a notice of delisting or failure to satisfy a continued listing rule or standard, but does not provide the specific reasons.
What changes in control have occurred at Evoke Pharma?
The filing reports a change in control of the registrant, but does not specify the nature or parties involved in the change.
Are there any changes in Evoke Pharma's executive officers or board of directors mentioned?
Yes, the filing mentions the departure of directors or certain officers, election of directors, and appointment of certain officers.
What material modifications have been made to the rights of Evoke Pharma's security holders?
The filing states there have been material modifications to the rights of security holders, but does not detail these modifications.
Filing Stats: 2,187 words · 9 min read · ~7 pages · Grade level 11.1 · Accepted 2025-12-17 09:08:40
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share EVOK The Nasdaq Stock Mar
- $11.00 — the Company (the "Company Shares"), for $11.00 in cash per Company Share, without inte
Filing Documents
- d81175d8k.htm (8-K) — 42KB
- d81175dex31.htm (EX-3.1) — 8KB
- d81175dex32.htm (EX-3.2) — 67KB
- 0001193125-25-321801.txt ( ) — 258KB
- evok-20251217.xsd (EX-101.SCH) — 3KB
- evok-20251217_lab.xml (EX-101.LAB) — 18KB
- evok-20251217_pre.xml (EX-101.PRE) — 11KB
- d81175d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 2.1 Agreement and Plan of Merger, dated November 3, 2025, by and among QOL Medical, LLC, QOL-EOS Merger Sub, Inc. and the Company (incorporated by reference to Exhibit 2.1 on the Current Report on Form 8-K, filed on November 4, 2025).* 3.1 Third Amended and Restated Certificate of Incorporation of Evoke Pharma, Inc. (filed herewith). 3.2 Second Amended and Restated Bylaws of Evoke Pharma, Inc. (filed herewith). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Certain exhibits, annexes and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted exhibits, annexes and schedules upon request by the SEC; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any annexes or schedules so furnished.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 17, 2025 EEVOKE PHARMA, INC. By: /s/ Matthew J. D'Onofrio Name: Matthew J. D'Onofrio Title: Chief Executive Officer and Director